The Food and Drug Administration approved a first-of-its-kind rare-disease drug.

It is the first treatment for Alexander disease, which had only supportive care.

In the trial, walking speed stayed stable on the drug versus a 33% decline for controls.

Ionis has not yet disclosed what price it will set for Zanvastro.

How each outlet framed it
STAT
emphasizes treatment stabilized walking speed (33% decline in control) and hints early treatment of children improves motor function

Sources: STAT